GlaxoSmithKline

Landmark, a three-year research partnership involving Parkinson's UK, Imperial College London, and pharmaceutical companies, aims to sequence tissue samples from the Parkinson's UK Brain Bank to build a gene expression map, identify biomarkers, and discover new drug targets for Parkinson's disease. Funded by a £4m gift from the Gatsby charitable foundation, the project will use snRNAseq to analyze samples, producing a major dataset for global research and informing new treatments through Parkinson's Virtual Biotech.

5 in 6 Americans who tried to quit smoking in 2022 failed, highlighting ineffective treatments and lack of innovation. Despite the addiction killing 480,000 annually, no new class of drugs has been approved in nearly two decades. Drugmakers and the FDA are criticized for lackadaisical approaches and stringent approval standards, focusing more on profitable drugs for rare cancers. Advocates call for a 'Reduce to Quit' approach and more flexible FDA standards to address the public health crisis.

Citi Pharma, Pakistan's largest API producer, will export nutraceuticals to the US, expecting $3 million in export revenue with 25-30% profit margins. Nutraceuticals face less rigorous FDA regulation than pharmaceuticals, allowing for quicker market entry.

A. Lenore Ackerman discusses the potential use of oral sulopenem for uncomplicated UTIs, emphasizing its role in high-risk patients with multi-drug-resistant infections, cautioning against its broad use due to concerns over resistance development.

Niger launches malaria vaccine campaign in Gaya, aiming to reduce child mortality; RTS,S by GSK added to routine vaccination calendar. Expected to be 75% effective against severe malaria, with 5 million cases and over 5,000 deaths annually in Niger. Complemented by free mosquito nets and preventive medication.

A study compared the recombinant zoster vaccine (RZV) with the zoster vaccine live (ZVL) for efficacy and safety, finding RZV more effective with 90% efficacy against shingles. Despite rare adverse events like dermatomal reactions, RZV remains the preferred vaccine for varicella zoster virus (VZV) prevention, necessitating further monitoring and studies on its immunomodulatory effects.

FDA approves AstraZeneca's FluMist nasal spray flu vaccine for self-administration, the first of its kind. The vaccine, available through a third-party online pharmacy, requires a screening and eligibility assessment. Individuals aged 2-17 should still receive it from a caregiver.

FDA approves FluMist nasal spray flu vaccine for self- or caregiver-administration for ages 2-49, the first such vaccine. It contains weakened live influenza virus strains and requires a prescription. Available through third-party online pharmacies with screening for eligibility.

FDA approves AstraZeneca's FluMist nasal spray flu vaccine for self-administration, the first of its kind. The vaccine, initially approved in 2003 for healthcare provider administration, will be available via third-party online pharmacies after a screening and eligibility assessment. Individuals aged 2-17 must still receive the vaccine from a caregiver.

FDA clears Eversense 365, the first 1-year CGM for diabetes. Approves lebrikizumab-lbkz for moderate-to-severe atopic dermatitis, benralizumab for eosinophilic granulomatosis with polyangiitis, and ribociclib plus aromatase inhibitor for HR+/HER2- early breast cancer.